Welcome to our dedicated page for The Oncology Institute news (Ticker: TOI), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute reports developments in value-based community oncology care, combining oncology and hematology services with specialty pharmacy, patient services, clinical trials, transfusions, and related care models. Its updates center on operating results, specialty pharmacy volume, gross profit and cash flow trends, and the performance of capitated and Medicare Advantage payor relationships.
Company news also covers participation in CMS oncology payment models, contract expansion across community oncology markets, clinical pathway and provider engagement initiatives, investor conference appearances, and governance or compliance leadership changes. The business operates through Specialty Pharmacy, Patient Services, and Clinical Trials and Other segments.
The Oncology Institute (TOI) will release its fourth quarter and full year results on March 10, 2022, after market close. Following the results, a conference call is scheduled for 5:00 p.m. ET, accessible via phone or webcast. TOI specializes in delivering advanced, value-based cancer care to over 1.5 million patients, with 54 clinic locations and a team of 80+ clinicians. Their services include clinical trials, stem cell transplants, and transfusions. Interested parties can join the call and access a replay through the provided contact information.
The Oncology Institute of Hope and Innovation (NASDAQ: TOI) has expanded its footprint by opening its 54th clinic in Lakeland, Florida, enhancing oncology services available in Polk County. This new clinic, which is the sixth in Florida, aims to provide patients with convenient access to oral chemotherapeutics and blood transfusion services. With experienced providers onboard, the institute continues to showcase its commitment to value-based cancer care. The expansion aligns with TOI's efforts to elevate healthcare standards and meet growing patient needs in the region.
Summary not available.
TOI has expanded its physician network by acquiring the practices of Dr. Ellsworth R. Grant and Dr. Leo E. Orr, adding to its team of over 80 clinicians. This acquisition will enhance TOI's ability to provide value-based oncology care to more than 1.5 million patients across its locations.
The new facility in Westlake offers advanced medical services similar to other TOI clinics, enhancing patient access to high-quality cancer care.
The Oncology Institute (TOI) has successfully completed its business combination with DFP Healthcare Acquisitions Corp., with approval received on November 12, 2021.
This merger, now valued at $842 million, enables TOI to retain approximately $133 million for growth initiatives. TOI’s stock began trading on NASDAQ under the symbols 'TOI' and 'TOIIW'. With a history of providing high-quality cancer care to over 150,000 patients across four states, TOI aims to disrupt the $200 billion U.S. oncology market through a value-based care model.
The Oncology Institute (NASDAQ: TOI) has completed its fourth acquisition in Q4 by acquiring the practice of Dr. Honghao Yang and his two oncology clinics in California. This expands TOI's coverage in the San Gabriel Valley, complementing its existing locations. Dr. Yang has over 30 years of experience and is recognized for his patient care approach. The new clinics will have multilingual staff to serve diverse communities. TOI aims to enhance its operational capacity and patient services through this integration.
The Oncology Institute (TOI) has successfully completed its merger with DFP Healthcare Acquisitions Corp., with the transaction approved on November 12, 2021. This merger establishes TOI as a public company, trading under the new ticker symbols 'TOI' and 'TOIIW' on NASDAQ. The transaction values TOI at $842 million, with a significant cash infusion of approximately $334 million, including $275 million from a private placement. The funds will support expansion initiatives across multiple states, driving TOI's value-based oncology care strategy.